---
layout: default
title: Ipratropium Bromide
parent: 僅模型預測 (L5)
nav_order: 212
evidence_level: L5
indication_count: 0
---

# Ipratropium Bromide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ipratropium Bromide: Evaluation Incomplete — No TxGNN Repurposing Prediction Available

---

## One-Sentence Summary

Ipratropium bromide is a well-established anticholinergic bronchodilator, widely used for the management of COPD and bronchospasm. However, this Evidence Pack contains **no TxGNN-generated repurposing predictions**, and critical data — including mechanism of action, safety warnings, and South African market registration records — are absent. A complete repurposing evaluation cannot be performed until these data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not captured in Evidence Pack *(known clinically: COPD, bronchospasm, asthma)* |
| Predicted New Indication | **None** — TxGNN prediction was not generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No prediction available |
| South Africa Market Status | Not registered (0 SAHPRA registrations found) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

> ⚠️ **Data Quality Flag:** Ipratropium bromide (e.g., Atrovent®) is a globally available bronchodilator. Zero SAHPRA registrations is unexpected and likely reflects a **data query mismatch** (e.g., spelling variant or salt-form mismatch) rather than true market absence. Manual verification against the SAHPRA online register is strongly recommended before drawing any regulatory conclusions.

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction has been generated for this drug in the current Evidence Pack. Therefore, no mechanism-based rationale for a new indication can be provided at this time.

**General pharmacological context (from public knowledge):** Ipratropium bromide is a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3). By blocking parasympathetic bronchoconstriction and secretomotor tone, it produces bronchodilation and reduces mucus secretion. This cholinergic blockade mechanism may have relevance beyond the respiratory tract — including secretion control, gastrointestinal motility, and vagal tone modulation — but **no TxGNN-derived predicted indication is available to anchor a repurposing rationale in this report**.

Once TxGNN predictions are generated and validated, this section will be populated with mechanistic linkage analysis connecting the original indication to the predicted new target.

> **Note on DrugBank query:** The query log records a *successful* DrugBank lookup (`result_status: success`, `result_count: 1`), yet `drugbank_id` remains `null` in the drug record. This is a **data pipeline inconsistency** that should be investigated and resolved before re-running the prediction workflow.

---

## Clinical Trial Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Clinical trial evidence cannot be mapped to a repurposing target at this stage.

---

## Literature Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Literature evidence cannot be mapped to a repurposing target at this stage.

---

## South Africa Market Information

No SAHPRA registration records were found for Ipratropium Bromide in the current data pull.

> ⚠️ **Verification Required:** Ipratropium bromide preparations (e.g., Atrovent® by Boehringer Ingelheim) are known to be registered and routinely dispensed in South Africa, including in public sector formularies. A **manual search of the SAHPRA online register** using the INN "ipratropium" is strongly recommended to retrieve confirmed registration numbers, approved dosage forms, and the current Professional Information (PI) document.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is incomplete — no TxGNN repurposing predictions were generated, SAHPRA registration data could not be verified, and all safety fields (warnings, contraindications, drug interactions) are absent. A meaningful repurposing evaluation cannot be completed under current conditions.

**To proceed, the following is needed:**

- [ ] **Re-run TxGNN pipeline** with "Ipratropium Bromide" to generate repurposing candidate predictions
- [ ] **Resolve DrugBank pipeline issue** — the query returned 1 result but `drugbank_id` was not stored; confirm the DrugBank ID and extract MOA, drug categories, and toxicity data
- [ ] **Manually verify SAHPRA registration status** — search the SAHPRA register for "ipratropium" to retrieve registration numbers and approved Professional Information
- [ ] **Extract safety data from PI** — populate key warnings, contraindications, and known drug interactions for the South African-approved formulation
- [ ] **Re-populate `original_indications`** from SAHPRA-approved labelling or DrugBank approved indication field
- [ ] **Resubmit Evidence Pack** for full evaluation once all Blocking (DG001) and High (DG002) data gaps are resolved

---

*This report is intended for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before any therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

